Journal

FDA Registration Is Not FDA Approval

Registration means the agency received a filing. It says nothing about approval or CGMP compliance.

What registration actually certifies

FDA states it plainly: registration means only that the agency received the information required to register the facility. It is not approval, and it is not a finding of CGMP compliance.

The gap is concrete. Of 48 facilities newly registered since June 2021, 39 had never been inspected as of July 2025 — a facility can register, compound and ship nationwide before any inspection occurs.

What an inspection record actually says?

A Form 483 lists observations made by an investigator at the close of an inspection. It is not a final agency determination, the firm has an opportunity to respond, and the outcome — not the observation — determines regulatory standing.

An action status of 'Open' means FDA has not decided whether further action will be taken. It records the absence of a decision, not the presence of a finding. A warning letter is different: it states the agency's position that specific violations occurred, scoped to what it says.

Why a 483 is weak signal on its own?

Of the 55 registered outsourcing facilities FDA had inspected as of July 2025, 53 had been issued a Form 483. Observations are close to universal in this sector, so their presence distinguishes almost nothing.

The more informative figure runs the other way: 39 of the 48 facilities newly registered since June 2021 had never been inspected at all. An absence of inspection data usually means an absence of inspection rather than a clean result.

Reading a record correctly

Registration and inspection are facility-specific. A company may operate several registered sites with different histories, and a finding at one says nothing about another.

Current and historical are also distinct states. A resolved warning letter reported as a current finding is the most damaging common error in this sector, and closeout status is what separates them.

What would change this analysis?

Three things would. A final determination on the 503B bulks list proposal, which the closed docket now makes likely within months. A change in the approved-product pricing that has repriced the category — the $149 oral tier is recent and competitive pressure has been moving it. And any published pharmacokinetic work on compounded preparations, which would move several questions here from unmeasured to measured.

None of those is speculative. Each has a named decision-maker and, in two cases, a live process. This page carries its own date so the gap between what was checked and what is current stays visible.

How to check any of this yourself

Regulatory framework: FDA's compounding pages carry the statutory position and the declaratory orders that ended the shortage exception. Every framework claim on this platform links to one of them.

Facility status: FDA's registered outsourcing facility list is updated weekly and now publishes inspection dates, whether a Form 483 was issued, and the action status. State licensure sits with the relevant board of pharmacy — a different register, and the only one covering 503A pharmacies.

Pricing: every figure here is a dated capture against the provider's own published page, computed as a total. The full dataset is published as JSON and CSV so the arithmetic can be rerun.

Applying this to fda registered pharmacy meaning

Registration means the agency received a filing. It says nothing about approval or CGMP compliance.

Everything above is checkable against a named public record. Where this platform has not performed that check, the field renders as an explicit status rather than an inferred value — which tells you precisely what to go and confirm.

Sources

• GLP-1 pricing database
• FDA — Registered Outsourcing Facilities
• FDA — Information for Outsourcing Facilities
• FDA — Q&A: Outsourcing Facility Registration

Update history

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.